- Home
- HYFM vs HOOK Comparison
HYFM vs HOOK Comparison
Compare HYFM & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- HOOK
- Stock Information
- Founded
- HYFM 1977
- HOOK 2011
- Country
- HYFM United States
- HOOK United States
- Employees
- HYFM N/A
- HOOK N/A
- Industry
- HYFM Industrial Machinery/Components
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- HOOK Health Care
- Exchange
- HYFM Nasdaq
- HOOK Nasdaq
- Market Cap
- HYFM 17.3M
- HOOK 15.3M
- IPO Year
- HYFM 2020
- HOOK 2019
- Fundamental
- Price
- HYFM $3.97
- HOOK $1.19
- Analyst Decision
- HYFM Hold
- HOOK Buy
- Analyst Count
- HYFM 2
- HOOK 4
- Target Price
- HYFM $7.00
- HOOK $10.67
- AVG Volume (30 Days)
- HYFM 6.9K
- HOOK 60.2K
- Earning Date
- HYFM 08-07-2025
- HOOK 08-07-2025
- Dividend Yield
- HYFM N/A
- HOOK N/A
- EPS Growth
- HYFM N/A
- HOOK N/A
- EPS
- HYFM N/A
- HOOK N/A
- Revenue
- HYFM $176,650,000.00
- HOOK $9,351,000.00
- Revenue This Year
- HYFM $5.45
- HOOK N/A
- Revenue Next Year
- HYFM $5.33
- HOOK N/A
- P/E Ratio
- HYFM N/A
- HOOK N/A
- Revenue Growth
- HYFM N/A
- HOOK N/A
- 52 Week Low
- HYFM $1.50
- HOOK $0.72
- 52 Week High
- HYFM $8.55
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- HYFM 58.98
- HOOK 37.08
- Support Level
- HYFM $3.51
- HOOK $1.13
- Resistance Level
- HYFM $3.94
- HOOK $1.25
- Average True Range (ATR)
- HYFM 0.27
- HOOK 0.06
- MACD
- HYFM 0.01
- HOOK -0.01
- Stochastic Oscillator
- HYFM 94.24
- HOOK 26.94
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.